Edition:
India

Avid Bioservices Inc (CDMO.OQ)

CDMO.OQ on NASDAQ Stock Exchange Capital Market

3.28USD
19 Apr 2018
Change (% chg)

$0.15 (+4.79%)
Prev Close
$3.13
Open
$3.16
Day's High
$3.34
Day's Low
$3.10
Volume
45,757
Avg. Vol
80,132
52-wk High
$5.77
52-wk Low
$2.25

Chart for

About

Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products... (more)

Overall

Beta: 2.50
Market Cap(Mil.): $151.07
Shares Outstanding(Mil.): 45.10
Dividend: --
Yield (%): --

Financials

  CDMO.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.58 -- --
ROI: -36.53 14.84 14.38
ROE: -48.18 16.34 16.07

BRIEF-Avid Bioservices Selected By Acumen Pharmaceuticals To Lead Process Development And Clinical Manufacture Of Novel Alzheimer's Disease Candidate

* AVID BIOSERVICES SELECTED BY ACUMEN PHARMACEUTICALS TO LEAD PROCESS DEVELOPMENT AND CLINICAL MANUFACTURE OF NOVEL ALZHEIMER’S DISEASE CANDIDATE

01 Mar 2018

BRIEF-Avid Bioservices Announces Proposed Offering Of Common Stock

* AVID BIOSERVICES ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

15 Feb 2018

BRIEF-Avid Bioservices, Oncologie Enter Into Asset Assignment, Purchase Agreement For Avid's PS-Targeting Program Including Bavituximab

* AVID BIOSERVICES AND ONCOLOGIE ENTER INTO ASSET ASSIGNMENT AND PURCHASE AGREEMENT FOR AVID’S PS-TARGETING PROGRAM INCLUDING BAVITUXIMAB

12 Feb 2018

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥3,758 +34.00
HANALL BIOPHARMA (009420.KS) ₩32,000.00 0.00
Pfizer Inc. (PFE.N) $36.53 +0.04
Johnson & Johnson (JNJ.N) $127.55 -0.17
Novartis AG (NOVN.S) CHF76.26 -1.02
Merck & Co., Inc. (MRK.N) $58.64 -0.28
Roche Holding Ltd. (ROG.S) CHF216.50 0.00
Roche Holding Ltd. (RO.S) CHF220.00 -0.20
Bayer AG (BAYGn.DE) €99.61 +0.01
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates